Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors

IL290527BActive Publication Date: 2026-08-01INCYTE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IL290527
Authority / Receiving Office
IL · IL
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-14
Filing Date
2020-08-13
Publication Date
2026-08-01
Estimated Expiration
2040-08-13

AI Technical Summary

Technical Problem

Current therapies lack effective CDK2 inhibitors, which are crucial for targeting cancer associated with deregulated CDK2 activity, as existing approaches have not resulted in approved agents targeting CDK2 despite significant efforts.

Method used

Development of imidazolyl pyrimidinylamine compounds that specifically inhibit CDK2, which are designed to be administered to patients with specific biomarker profiles indicative of CDK2-related disorders, such as amplification of the CCNE1 gene or elevated CCNE1 expression, to effectively target and inhibit the enzyme.

Benefits of technology

The imidazolyl pyrimidinylamine compounds selectively inhibit CDK2, offering a novel approach to treating cancers with deregulated CDK2 activity by targeting specific biomarker profiles, potentially restoring sensitivity to other treatments and inhibiting tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000465_0000
    Figure 00000465_0000
  • Figure 00000466_0000
    Figure 00000466_0000
  • Figure 00000466_0001
    Figure 00000466_0001
Patent Text Reader

Abstract

The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Need to check novelty before this filing date? Find Prior Art